Interpharma Pty Ltd v Commissioner of Patents

Link copied
Case Copied 54 min read

FEDERAL COURT OF AUSTRALIA

Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1498

PATENT – Infringement – Pharmaceutical compound – No claim for particular stereochemistry – Whether racemate only claimed – Whether claims covered β anomer.

PATENT – Validity – Pharmaceutical compound – Utility – Whether invention useful according to promises in patent – Whether toxicity compromises utility.

PATENT – Infringement – Process for manufacture of chemical compound.

PATENT – Validity – Process for manufacture of chemical compound – Whether invention lacked inventive step – Common general knowledge – Whether lack of inventive step established an interlocutory application.

INTERLOCUTORY INJUNCTION – Alleged infringement of patent – Whether prima facie case made out – Whether defences of invalidity made out – Necessary strength of defences on interlocutory application – Whether damages an adequate remedy – Balance of convenience – Alleged infringer entering established market – Whether possible to restore applicant to present position – Relevance of apparent strength of substantive cases.   

Patents Act 1990 (Cth) ss 18(1)(b), 18(1)(c), 78

AB Hassle v Pharmacia (Australia) Pty Ltd (1995) 33 IPR 63
Aktiebolaget Hassle and Anor v Alphapharm Pty Ltd (2002) 212 CLR 411
Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559
Apotex Pty Ltd v Sanofi-Aventis [2008] FCA 194

Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57

Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618

Castlemaine Tooheys Ltd v South Australia (1986) 161 CLR 148

GenRx Pty Ltd v Sanofi-Aventis (2007) 73 IPR 502

Hexal Australia Pty Ltd v Roche Therapeutics Inc (2005) 66 IPR 325
Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1283
Merck & Co Inc v GenRx Pty Ltd (2006) 70 IPR 286

Minnesota Mining & Manufacturing Co v Tyco Electronics Pty Ltd (2002) 56 IPR 248

Pharmacia Italia SpA v Interpharma Pty Ltd (2005) 67 IPR 397

Plimpton v Spiller (1876) 4 Ch D 286
Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC [2008] FCAFC 82
Tidy Tea Ltd v Unilever Australia Ltd (1995) 32 IPR 405

INTERPHARMA PTY LTD v THE COMMISSIONER OF PATENTS; ELI LILLY & COMPANY and ELI LILLY AUSTRALIA PTY LTD; INTERPHARMA PTY LTD

VID 160 of 2008

JESSUP J
10 OCTOBER 2008
MELBOURNE

IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

VID 160 of 2008

BETWEEN:

INTERPHARMA PTY LTD
Applicant

ELI LILLY & COMPANY
First Cross-Claimant

ELI LILLY AUSTRALIA PTY LTD
Second Cross-Claimant

AND:

THE COMMISSIONER OF PATENTS
Respondent

INTERPHARMA PTY LTD
Cross-Respondent

JUDGE:

JESSUP J

DATE OF ORDER:

10 OCTOBER 2008

WHERE MADE:

MELBOURNE

UPON the cross-claimants by their counsel undertaking:

(a)to submit to such order (if any) as the court may consider to be just for the payment of compensation, to be assessed by the court or as it may direct, to any person, whether or not a party, adversely affected by the operation of the interlocutory order or undertaking or any continuation (with or without variation) thereof; and

(b)to pay the compensation referred to in (a) to the person…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Interpharma Pty Ltd v Commissioner of Patents and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2008] FCA 1498
Decision Date

CaseChat Overview and Summary

The case of Interpharma Pty Ltd v Commissioner of Patents involved a dispute over the validity and infringement of patents related to gemcitabine hydrochloride, a pharmaceutical compound. Interpharma, the cross-claimant, alleged that the respondent, Health Care Direct Pty Ltd, was infringing on its patents through the production and distribution of the pharmaceutical product EBEGEMCIT. Interpharma sought interlocutory injunctions to prevent Health Care Direct from marketing EBEGEMCIT in Australia and from including it in the Pharmaceutical Benefits Scheme (PBS). The urgency of the application was due to the impending release of the PBS list, necessitating an application for withdrawal by a specific date to be effective.

The primary legal issues before the court were whether Health Care Direct's production and distribution of EBEGEMCIT infringed on Interpharma's patents and whether an interlocutory injunction should be granted to restrain Health Care Direct from marketing the product. The court had to consider the validity of Interpharma's patents, the nature of the alleged infringement, and the potential impact of the injunction on Health Care Direct's operations and the PBS listing process. The court also needed to balance the urgency of the situation with the need for a fair hearing of the merits of the case.

In its decision, the court found that Interpharma had established a serious question to be tried regarding the validity of the patents in question. The court concluded that the cross-claimant had made out a prima facie case of patent infringement and that an interlocutory injunction was warranted. The court emphasised the need for Health Care Direct to withdraw its application for the inclusion of EBEGEMCIT in the PBS to avoid any practical effect, given the administrative timeline for PBS updates. The court granted the relief sought by Interpharma, including an injunction against the marketing of EBEGEMCIT and a requirement for Health Care Direct to withdraw its PBS application. The court also set out a detailed timetable for the discovery process and the trial, reserving costs for later determination.

The court's final orders included restraining Health Care Direct from marketing and distributing EBEGEMCIT, requiring the withdrawal of the PBS application, and establishing a timeline for document discovery and trial preparation. The court mandated specific dates for the filing and serving of documents and affidavits, and set a trial date for June 2009, with an estimated duration of 10 days. The parties were granted liberty to apply for further orders as necessary.

Orders

Orders of the court

1. The cross-respondent, whether by its servants, agents or otherwise, be restrained until the hearing and determination of this proceeding or further order from making, importing, selling, offering to sell, otherwise disposing of, offering otherwise to dispose of or keeping for any of those purposes, the following pharmaceutical formulations;

(a) EBEGEMCIT gemcitabine 200mg (as hydrochloride) powder for injection vial having ARTG Number 129350; and

(b) EBEGEMCIT gemcitabine 1g (as hydrochloride) powder for injection vial having ARTG Number 129351.

2. The cross-respondent, whether by its servants, agents or otherwise, be restrained until the hearing and determination of this proceeding or further order from making, importing, selling, offering to sell, otherwise disposing of, offering otherwise to dispose of or keeping for any of those purposes, any gemcitabine hydrochloride formulation wherein the active pharmaceutical ingredient was (or will be) manufactured by ScinoPharm Taiwan Limited.

3. The cross-respondent, by 12 noon on Tuesday, 14 October 2008, take all steps as are necessary to withdraw its application for the inclusion of the EBEGEMCIT gemcitabine hydrochloride formulations referred to in paragraph 1 above on the Schedule of Pharmaceutical Benefits and serve on the Cross-Claimants an affidavit made by a proper officer of the Cross-Respondent’s identifying each of the steps that have been taken.

4. The cross-respondent, whether by its servants, agents or otherwise, be restrained until the hearing and determination of this proceeding or further order from making any application for the inclusion of a gemcitabine hydrochloride formulation on the Schedule of Pharmaceutical Benefits wherein the active pharmaceutical ingredient was (or will be) manufactured by ScinoPharm Taiwan Limited.

5. Costs be reserved.

6. All issues as to liability are to be heard prior to, and separately from, any issues as to quantum.

7. Each party file and serve on or before 24 October 2008 a list of categories of documents of which they seek discovery by the opposite party, such categories to be confined to those documents likely to be relevant and useful at the trial.

8. Each party to make discovery of the categories of documents sought by the opposing party on or before 28 November 20087.

9. Each of the parties to file and serve on or before 16 January 2009 any affidavits upon which they intend to rely in chief at the trial of this proceeding.

10. Each of the parties to file and serve on or before 27 March 2009 any affidavits on which they intend to rely in answer at the trial of this proceeding.

11. Each of the parties to file and serve on or before 1 May 2009 any affidavits in reply upon which they intend to rely at the trial of this proceeding.

12. The trial of this proceeding to be fixed for hearing on the first available date on or after 1 June 2009 with an estimate of 10 days.

13. Each party have liberty to apply on 3 days’ written notice.

Background

Background to the litigation

The cross-claimants allege that EBEGEMCIT infringes the compound patent, and that the process used in the production of Ebegemcit infringes the process patent. As I have indicated, they seek interlocutory injunctions to restrain the cross-respondent from marketing Ebegemcit in Australia. The mandatory interlocutory injunction sought by the cross-claimants would, if granted, require the cross-respondent to withdraw its application for the inclusion of EBEGEMCIT in the PBS. However, the court has been informed that, because of the administrative steps associated with the preparation of the list of pharmaceuticals due to be released on 1 December 2008, unless an application for withdrawal is made by about 16 October 2008 at the latest, it will be unlikely to have any practical effect. That circumstance constitutes part of the explanation for the urgency with which the present interlocutory application has been heard and decided. background to the present application In May 2003, the cross-respondent executed an exclusive supply and distribution agreement with an Austrian company, EBEWE Pharma GES.m.b.H. Nfg.KG (“EBEWE”). That agreement gave the cross-respondent the exclusive right to distribute EBEWE oncology and other pharmaceutical products in Australia and New Zealand. The cross-respondent conducted an official “launch” of the EBEWE oncology products in Australia in April 2005. However, it was not until 2007 that preparations were made for the introduction into this range of a product in which the active ingredient was gemcitabine hydrochloride. That product was “Gemcitabine EBEWE”. Those preparations commenced in June 2007, but the managing director of the cross-respondent, Mr David Gray, said in his affidavit sworn on 23 June 2008 that the production of “launch materials” could not commence until Gemcitabine EBEWE obtained registration on the ARTG. In his affidavit of 23 June 2008, Mr Gray swore as follows:I can recall discussing the patent position in relation to gemcitabine HCl compound with Dr. Schnait who is responsible for pharmaceutical development at EBEWE Pharma during product development and launch meetings in late 2005 and during 2006/2007. I was told by Dr Schnait and believe that Eli Lilly and Company had a patent in Austria for the compound gemcitabine HCl which covered the treatment of cancer and was due to expire in March 2009. Dr Schnait also told me that he could not find any equivalent patents in Australia when he undertook his searches of the patent databases.On the basis of what I had been told by Dr Schnait of EBEWE Pharma I believed that there was no current patent in Australia which covered the compound gemcitabine HCI and I was not aware of the Anti-Viral Patent and the Decision until 2 August 2007.The “anti-viral patent” referred to by Mr Gray is the compound patent, and the “decision” is the decision to extend the term of that patent to 7 March 2009. What happened on 2 August 2007 was that the cross-respondent was informed by its solicitors of the existence of the compound patent and the extension of term. Over the next few months, the cross-respondent caused investigations to be made about the compound patent, and considered, amongst other things, whether the extension of term could be challenged. In October 2007, it applied to have Gemcitabine EBEWE registered on the ARTG.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

JESSUP J

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Established by: JESSUP J

Full text does not contain this section.